Physician profile
Devri Burnell
NPI 1700512795
$2,139.89
in general payments reported to CMS, 2019-2025
21 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $99.51 · 2024: $456 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074 · Travel and Lodging: $1,030 · Education: $36.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,074.04 |
| Travel and Lodging | $1,029.85 |
| Education | $36.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,357.13 | 2025 | Interstim |
| Abbvie INC. | $274.53 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $57.75 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $54.10 | 2024-2025 | Auvelity |
| Novo Nordisk INC | $43.66 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $36.12 | 2023-2024 | Enbrel, Evenity, Prolia |
| Janssen Biotech, INC. | $35.54 | 2025 | Erleada |
| Sanofi Pasteur INC. | $35.20 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $30.30 | 2024 | Rexulti |
| Ucb, INC. | $29.09 | 2024 | Bimzelx |
| Sumitomo Pharma America, INC. | $25.84 | 2025 | Gemtesa |
| Immunitybio, INC. | $23.20 | 2025 | |
| Teleflex LLC | $20.49 | 2025 | Urolift |
| 180 Medical, INC. | $18.04 | 2025 | |
| Phathom Pharmaceuticals, INC. | $16.56 | 2024 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $16.18 | 2024 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.70 | 2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.25 | 2024 | Caplyta |
| Daiichi Sankyo INC. | $13.22 | 2024 | Injectafer |
| Idorsia Pharmaceuticals US INC | $12.91 | 2023 | Quviviq |
| Laborie Medical Technologies Corp. | $12.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devri Burnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.